PR GILLES SALLES (MD, PHD)
Head of the Hematology Department
Hospices Civils de Lyon
Université Claude Bernard Lyon, France

"REVIEW AND NEW DEVELOPMENTS IN REFRACTORY OR RECURRENT INDOLENT LYMPHOMA"

TUESDAY, APRIL 4, 2017
Hôpital de l'Enfant-Jésus (Québec)
Salle N1732 (FRENCH TALK)
08:00 to 09:00
Visio – IRIS # 409658

WEDNESDAY, APRIL 5, 2017
Hôpital Maisonneuve-Rosemont
Room 0-80 (Pavillon Marcel Lamoureux)
(FRENCH TALK)
12:00 to 13:00
Visio – IRIS # 409681

Hôpital Notre-Dame
Amphithéâtre Deschamps
(FRENCH TALK)
17:00 to 18:00
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

THURSDAY, APRIL 6, 2017
Jewish General Hospital
Room E-711 (ENGLISH TALK)
12:30 to 13:30
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510
Visio – IRIS # 398943

Hôpital du Sacré-Cœur de Montréal
Room G-4130 (FRENCH TALK)
15:00 to 16:00
Visio – IRIS # 271123

FRIDAY, APRIL 7, 2017
Hôpital Charles Le Moyne
Room HN-106 (FRENCH TALK)
09:00 to 10:00

Visioconference Request: vspo@mcgill.ca

LEARNING OBJECTIVES
At the end of the session, the participant will be able to:

• Identify the biological and clinical factors influencing treatment initiation as well as the choice of treatment for patients with relapsed or refractory disease.
• Recognize the indication and management of toxicities associated with new available therapies.
• Identify new future therapies for this population.

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcm. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Apobiologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seattle Genetics